HG
Hansen Gwenn Chief Scientific Officer
OFFICER F
US US · SEC (Form 4)
Explore the complete record of transactions filed by Hansen Gwenn, Chief Scientific Officer. Officer active across 1 companies, notably Nurix Therapeutics, Inc.. In total, 25 disclosures have been logged. The latest transaction was disclosed on 30 October 2025 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Declarations 25 total
03,207 shares 0
Common Stock
SEC:0001817160-25-000005 · 30 Oct 2025
03,207 shares 0
Common Stock
SEC:0001817160-25-000005:0 · 30 Oct 2025
03,206 shares 0
Common Stock
SEC:0001209191-22-026892:0 · 30 Apr 2022
€2,553 400 shares @ €6.3833 0.0001% mcap 6.9% of flow
Common Stock
SEC:0001209191-22-000730 · 3 Jan 2022
€2,553 400 shares @ €6.3833 0.0001% mcap 3.5% of flow
Common Stock
SEC:0001209191-22-000730:0 · 3 Jan 2022
€2,563 400 shares @ €6.4076 0.0001% mcap 6.9% of flow
Common Stock
SEC:0001209191-21-067685 · 1 Dec 2021
€2,563 400 shares @ €6.4076 0.0001% mcap 3.5% of flow
Common Stock
SEC:0001209191-21-067685:0 · 1 Dec 2021
€2,513 400 shares @ €6.2821 0.0001% mcap 6.8% of flow
Common Stock
SEC:0001209191-21-062466 · 1 Nov 2021
€2,513 400 shares @ €6.2821 0.0001% mcap 3.4% of flow
Common Stock
SEC:0001209191-21-062466:0 · 1 Nov 2021
€2,503 400 shares @ €6.2586 0.0001% mcap 6.8% of flow
Common Stock
SEC:0001209191-21-061973 · 27 Oct 2021
€2,503 400 shares @ €6.2586 0.0001% mcap 3.4% of flow
Common Stock
SEC:0001209191-21-061973:0 · 27 Oct 2021
€2,509 400 shares @ €6.2724 0.0001% mcap 6.8% of flow
Common Stock
SEC:0001209191-21-059064 · 1 Oct 2021
€2,509 400 shares @ €6.2724 0.0001% mcap 3.4% of flow
Common Stock
SEC:0001209191-21-059064:0 · 1 Oct 2021
€9,808 1,600 shares @ €6.1299 0.0005% mcap 26.5% of flow
Common Stock
SEC:0001209191-21-055171 · 7 Sept 2021
€9,808 1,600 shares @ €6.1299 0.0005% mcap 13.3% of flow
Common Stock
SEC:0001209191-21-055171:0 · 7 Sept 2021
€2,453 400 shares @ €6.1313 0.0001% mcap 6.6% of flow
Common Stock
SEC:0001209191-21-054434 · 1 Sept 2021
€2,453 400 shares @ €6.1313 0.0001% mcap 3.3% of flow
Common Stock
SEC:0001209191-21-054434:0 · 1 Sept 2021
€2,446 400 shares @ €6.1139 0.0001% mcap 6.6% of flow
Common Stock
SEC:0001209191-21-049420 · 2 Aug 2021
€2,446 400 shares @ €6.1139 0.0001% mcap 3.3% of flow
Common Stock
SEC:0001209191-21-049420:0 · 2 Aug 2021
€2,451 400 shares @ €6.1285 0.0001% mcap 6.6% of flow
Common Stock
SEC:0001209191-21-044868 · 1 Jul 2021
€2,451 400 shares @ €6.1285 0.0001% mcap 3.3% of flow
Common Stock
SEC:0001209191-21-044868:0 · 1 Jul 2021
€2,377 400 shares @ €5.9422 0.0001% mcap 6.4% of flow
Common Stock
SEC:0001209191-21-037263 · 1 Jun 2021
€2,377 400 shares @ €5.9422 0.0001% mcap 3.2% of flow
Common Stock
SEC:0001209191-21-037263:0 · 1 Jun 2021
€4,815 800 shares @ €6.0193 0.0003% mcap 13.0% of flow
Common Stock
SEC:0001209191-21-029883 · 3 May 2021
€4,815 800 shares @ €6.0193 0.0003% mcap 6.5% of flow
Common Stock
SEC:0001209191-21-029883:0 · 3 May 2021
About Hansen Gwenn Hansen Gwenn is the Chief Scientific Officer of Nurix Therapeutics, Inc. He oversees the company's research and development initiatives.